The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
HOME > ARCHIVE
ARCHIVE
- Kemporen Proposes Series of Measures to Contain Medical Spending
March 5, 2001
- Fujisawa Ties Up with Fuji RC for Respiratory Care Devices
March 5, 2001
- Dissolution Test Methods Proposed for 13 Active Ingredients
March 5, 2001
- MIC Receives Applications for Clinical Trials via Toll-free Dial
March 5, 2001
- Nomura Securities Starts Nomura Bio Network
March 5, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
March 5, 2001
- Novartis: Group Sales Up 10% to CHF 35.8 Bil.
March 5, 2001
- 60% of Manufacturer-hired MRs Are Interested in Contract MRs
March 5, 2001
- Korosho to Present Drug Pricing Reform Policy by Summer
March 5, 2001
- Raloxifene Reduces Risk of Breast Cancer
March 5, 2001
- BULLETIN
March 5, 2001
- Government Takes Measures against Stevens-Johnson Syndrome
March 5, 2001
- PMSB to Increase Awareness of Medical Devices Master File System
March 5, 2001
- EMA to Promote Generics Aiming at Medical Professionals
March 5, 2001
- Elderly Should Shoulder Costs of Social Security: Gov't Council
March 5, 2001
- Goodman Starts Clinical Trial of Catheter System for Intravascular Ultrasonic Therapy
March 5, 2001
- Eisai Aims at Sales of \400 Bil. in 2001: President Naito
March 5, 2001
- Draft Standards for Drugs Using Cells, Tissues Released
March 5, 2001
- KSD Introduces Medical Image Communication Software from India
March 5, 2001
- MTP Sets Up Subsidiary in UK for Independent Marketing of Novastan
March 5, 2001
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…